Pharmacovigilance in retail pharmacies for special or major diseases

doi:10.19803/j.1672-8629.20220591

Abstract

Abstract: Objective To explore how to exercise pharmacovigilance in retail pharmacies for special or major diseases (DTP pharmacies) so as to contribute to the construction of pharmacovigilance systems. Methods By means of field research and literature review, the characteristics, problems and solutions regarding pharmacovigilance in DTP pharmacies were described. Results Pharmacovigilance in DTP pharmacies is necessary, unique, representative and user-friendly, but is hindered by incompetence of practitioners, low trust from patients, imperfect pharmacovigilance mechanisms and a lack of targeted laws, regulations and guidelines. Conclusion It is recommended that pharmacovigilance professionals in DTP pharmacies should be better-trained, patients'trust enhanced through professional services and branding, and the pharmacovigilance mechanisms, related laws, regulations and guidelines revised.

Key words: drugs for special or major diseases, retail pharmacies, DTP pharmacy, pharmacovigilance, pharmaceutical care, safe drug use

CLC Number:

R952
R994.11

HUO Peiqiong, ZHENG Peng, SU Zhenhao. Pharmacovigilance in retail pharmacies for special or major diseases[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.

References

[1] People's Daily. To lay a solid and healthy foundation for the great rejuvenation of the Chinese nation[EB/OL]. (2021-08-08)[2022-09-25]. http://politics.people.com.cn/n1/2021/0808/c1001-32185136.html.
[2] LIU PC, ZHU Z, LIU F.Expert consensus on the construction of pharmacovigilance system in medical institutions[J]. China Drug Application and Monitoring(中国药物应用与监测), 2022, 19(3): 135-144.
[3] NPC. Drug Administration Law of the People's Republic of China[J]. Bulletin of the Standing Committee of the National People's Congress of the People's Republic of China(中华人民共和国全国人民代表大会常务委员会公报), 2019, 341(5): 771-788.
[4] NPC. Announcement of the State Food and Drug Administration on the release of the Good Management Practice for Pharmacovigilance[J] Bulletin of the State Council of the People's Republic of China(中华人民共和国国务院公报), 2021, 1741(22): 62-75.
[5] NMPA. The “Fourteenth Five-Year Plan” for National Drug Safety and Promotion of High Quality Development[N]. China Medical News(中国医药报), 2021-12-31(002).
[6] DUAN R, LI ZX.Bibliometric analysis of current status and hotspots of pharmacovigilance research at home and abroad[J]. China Pharmacy(中国药房), 2022, 33(1): 116-122.
[7] LIU LL.Inspiration to China from the pharmacovigilance supervision entrusted by foreign drug marketing license holders[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 773-776.
[8] SUN J, WANG JY, LIU PC, et al.Analysis of pharmacovigilance responsibilities of drug marketing license holders in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(10): 681-687.
[9] JIANG DN, LAI WJ, ZHAO XP, et al.Thoughts on the establishment of pharmacovigilance system by pharmaceutical group companies under the pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(6): 504-506.
[10] PENG LL, FAN Y, LIU W, et al.Discuss how drug manufacturers establish a pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(11): 666-670.
[11] SA RN, ZHANG B, LIN ZJ, et al.Discussion on the practice of Chinese medicine pharmacovigilance in pharmaceutical care of medical institutions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 422-426.
[12] HOU YF, SONG HB, LIU HL, et al.Practice and discussion on active monitoring based on Chinese hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 212-214.
[13] YAN Y, TAO QS, WEI H.Research on the development model of DTP pharmacy in China under the background of deepening the reform of medical security system[J]. Journal of Guangdong Pharmaceutical University(广东药科大学学报), 2021, 37(6): 35-40.
[14] HU J, XUE LJ, SHAO R.Research on American specialized pharmacy and its inspiration to China's DTP pharmacy[J]. Health Economics Research(卫生经济研究), 2018(11): 31-34.
[15] FAN XY, CHANG Y, ZHOU HN, et al.Analysis on the current situation and problems of DTP pharmacy market management in Guizhou province[J]. China Pharmacy(中国药房), 2022, 33(7): 789-794.
[16] ZHOU X, CHEN CR.Analysis on the development process and reasons of DTP pharmacy in China[J]. China Health Industry(中国卫生产业), 2019, 16(19): 191-193.
[17] DENG JD, WEN ZX.Report on the development of China's drug circulation industry (中国药品流通行业发展报告)[M]. Beijing: Social Science Literature Press, 2021: 329.
[18] QIANZHAN. Prospective Industry Research Institute Analysis of the market size and competition pattern of China's DTP pharmacy industry in2021 The policy will help the rapid growth of the retail size of the market[EB/OL]. (2021-09-18)[2022-09-25]. https://bg.qianzhan.com/report/detail/300/210918-247f9f45.html.
[19] WANG D, YAO Z, WANG Y, et al.The development of China's DTP pharmacy model from the perspective of medical separation[J]. Health Economics Research(卫生经济研究), 2018, 375(7): 9-11.
[20] Guidance of the Health and Health Commission of the Medical Insurance Bureau on establishing and improving the “double channel” management mechanism of national medical insurance negotiation drugs[J]. Bulletin of the State Council of the People's Republic of China(中华人民共和国国务院公报), 2021, 1738(19): 59-60.
[21] CHEN Y, DING JX, CHEN Y, et al.Research on DTP pharmacy management mode under the “dual channel” framework[J]. World Journal of Clinical Medicine(世界临床药物), 2021, 42(9): 725-733.
[22] ZHONG YY.Garden under the “dual channels”, DTP pharmacy has become the main force in the out of hospital market[J]. China Drugstore(中国药店), 2021(7): 22-23.
[23] ZENG SX. Innovative drug layout DTP both sides “confirm eyes” like this[N]. Pharmaceutical Economic News(医药经济报), 2021-06-24(B04).
[24] ZHOU J, LIU YZ, CHEN C.Thinking on the training approach of pharmacovigilance talents[J]. Guangdong Chemical Industry(广东化工), 2022, 49(11): 235-236.
[25] LI CH.Analysis of pharmaceutical service value of licensed pharmacists in retail pharmacies and suggestions for improvement[J]. China Pharmaceutical(中国药业), 2022, 31(14): 1-4.
[26] WANG ZY, LUO X, YE Z, et al.Investigation on the current situation of cancer pharmaceutical service capacity of DTP pharmacy in China[J]. China Pharmacy(中国药房), 2020, 31(9): 1132-1138.
[27] SHEN CY, WU TT, LIU W, et al.Thoughts on post marketing monitoring and evaluation of drugs in China in the new era[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(10): 649-652.
[28] NPC. Decision of the State Food and Drug Administration on the revision of the Good Manufacturing Practice for Pharmaceutical Products[J].Bulletin of the State Council of the People's Republic of China(中华人民共和国国务院公报), 2017, 1582(7): 75-92.
[29] China Pharmaceutical Business Association. Retail pharmacy operating special disease drug service specification[EB/OL]. (2019-12-27)[2022-09-25]. http://www.capc.org.cn/index.html/view-8cee42a19f054cc08d13e46b0d0f33b9-0a292a617ad64f47b12bb6128eae5e62.html.
[30] QIAN ZG, WANG YH, ZHU YJ, et al.Research on the extensibility of China's DTP pharmacy model in the context of drug separation[J]. China Health Administration(中国卫生事业管理), 2019, 36(5): 357-359.
[31] ZHOU RH.Research on DTP pharmacy mode in China from the perspective of medicine separation[J]. Medical Diet and Health(医学食疗与健康), 2020, 18(15): 204-212.
[32] NPC. Good Manufacturing Practice (revised in 2010)[J]. Bulletin of the Ministry of Health of the People's Republic of China(中华人民共和国卫生部公报), 2011, 91(2): 3-29.